Drug Trial Radar · NCT06368804
Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
196
Planned (sponsor's estimate)
Start
Sep 15, 2024
Primary completion
Mar 15, 2025
Study completion Sep 15, 2028
Sponsor
- Lead sponsor
- Centre Hospitalier Intercommunal CreteilAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Assistance Publique - Hôpitaux de Paris
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic airways infection with Pseudomonas aeruginosa (PA) is associated with increased frequency of exacerbations, deterioration in quality of life and increased mortality in adult patients with bronchiectasis. Current guidelines suggest the prescription of an eradication antibiotic treatment for a first episode of PA infection (early PA infection). Several antibiotic regimens may be proposed, ranging from a monotherapy with oral fluoroquinolone (FQ) to an intravenous cotherapy with the addition of inhaled antibiotics that seems to improve the rate of PA eradication. As no study strictly favoured one regimen, current practices are heterogeneous and could certainly benefit from stronger evidence, with both medical and economic impact.
Conditions
- Bronchiectasis
Interventions
Antibiotic monotherapy treatment and follow-upDrug
1. a 3-months treatment period, including: * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d) * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ; 2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Antibiotic bitherapy treatment and follow-upDrug
1. a 3-months treatment period, including: * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d) * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ; 2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Primary outcomes
What the sponsor says the trial is designed to measure.
- PA-eradication rateTime frame: 6 months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
CHU Amiens-Picardie
Amiens, France · Recruiting
CHU Haut Leveque, Bordeaux
Bordeaux, France · Recruiting
CHRU Brest
Brest, France · Recruiting
CH Pontoise
Cergy-Pontoise, France · Recruiting
Centre hospitalier intercommunal de Créteil
Créteil, France · Recruiting
APHP, Henri Mondor
Créteil, France · Recruiting
Hôpital de la Croix Rousse, HCL, Lyon
Lyon, France · Not yet recruiting
Clinique St Joseph
Marseille, France · Recruiting
CHU Nantes
Nantes, France · Recruiting
CHU H. Pasteur, Nice
Nice, France · Not yet recruiting
Hôpital Pitié Salpêtrière
Paris, France · Recruiting
APHP, Cochin
Paris, France · Recruiting
APHP, Saint Louis
Paris, France · Recruiting
APHP, Tenon
Paris, France · Recruiting
Hôpital Foch, Suresnes
Suresnes, France · Recruiting
CHU H. Larrey, Toulouse
Toulouse, France · Recruiting
CH Versailles
Versailles, France · Recruiting
CH Villefranche s/Saône
Villefranche-sur-Saône, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.